Overall survival for oncology drugs approved for genomic indications

Haslam, Alyson; Kim, Myung Sun; Prasad, Vinay

doi:10.1016/j.ejca.2021.10.028

Cited by 7 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Molecular therapy demonstrates remarkable response rates, making advances in reducing cancer mortality ( Siegel et al, 2021 ), although the response to genome-targeted therapy has been modest (2.73% in 2006 to 7.04% in 2020) and more trials are needed to determine the impact on survival, which currently stands at 4.7 months ( Haslam et al, 2021 ; Haslam et al, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

Tissue management in precision medicine: What the pathologist needs to know in the molecular era

Silva

Pinto²,

Cirnes³

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Precision medicine is “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.” Among many medical specialists involved in precision medicine, the pathologists play an important and key role in the implementation and development of molecular tests that are in the center of decision of many therapeutic choices. Besides many laboratory procedures directly involved in the molecular tests, is fundamental to guarantee that tissues and cells collected for analysis be managed correctly before the DNA/RNA extraction. In this paper we explore the pivotal and interconnected points that can influence molecular studies, such as pre-analytical issues (fixation and decalcification); diagnosis and material selection, including the calculation of nuclei neoplastic fraction. The standardization of sample processing and morphological control ensures the accuracy of the diagnosis. Tissue or cytological samples constitutes the main foundation for the determination of biomarkers and development of druggable targets. Pathology and precision oncology still have a long way to go in terms of research and clinical practice: improving the accuracy and dissemination of molecular tests, learning in molecular tumor boards for advanced disease, and knowledge about early disease. Precision medicine needs pathology to be precise.

show abstract

Section: Discussionmentioning

confidence: 99%

Tissue management in precision medicine: What the pathologist needs to know in the molecular era

Silva

Pinto²,

Cirnes³

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…The value for money of some commercialised drugs is one of the issues. In oncology, for example, ex post data have shown that several active principles have not lived up to their expectations, as the difference between the expected effectiveness and actual survival is large [ 16 ], and patient responses have been heterogeneous [ 17 ]. This evidence has reopened the debate on the use of risk-sharing arrangements and other forms of price reduction [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Timely, Cheap, or Risk-Free? The Effect of Regulation on the Price and Availability of New Drugs

Levaggi,

Levaggi

2024

Pharmacy

View full text Add to dashboard Cite

The high level of regulation of innovative drugs on the market, which is necessary to protect consumers, produces important effects on drug availability and innovation. In public healthcare systems, the need to curb prices comes from expenditure considerations. The aim of price regulation is to obtain a more equitable allocation of the value of an innovative drug between industries and patients (by reducing prices to make drugs more affordable), but it may also reduce access. (In the listing process, the industry may find it more convenient to limit commercialisation to profitable subgroups of patients.) Furthermore, with the advent of personalised medicine, there is another important dimension that has to be considered, namely, incentives to invest in drug personalisation. In this paper, we review and discuss the impact of different pricing rules on the expenditure and availability of new drugs.

show abstract

“…Although advanced early screening technology and diagnosis and treatment methods have improved the efficiency of diagnosis and treatment of NSCLC, most patients have progressed to the middle and late stage when they see the doctor, miss the optimal operation time, and have poor surgical tolerance [4] [5] [6] . According to statistics, the 5-year survival rate of NSCLC is extremely low, only about 20%, and the majority of deaths are elderly people over 60 years old [3] [7] [8] [9] . At present, although it is clinically possible to treat elderly NSCLC patients by means of surgery or chemotherapy, in order to achieve the purpose of clearing the disease and delaying the life cycle of the patient [10] [11] .…”

Section: Introductionmentioning

confidence: 99%

Difference of serum tumor markers in different clinical stages of elderly patients with non-small cell lung cancer and evaluation of diagnostic value

et al. 2023

View full text Add to dashboard Cite

Objective To explore the difference and diagnostic value evaluation of serum tumor markers in different clinical stages of elderly non-small cell lung cancer (NSCLC) patients. Methods Select 100 elderly NSCLC patients admitted to our hospital from June 2018 to June 2021, collect the general data, pathology data and imaging data of the patients, and the patients were divided into I-IV clinical stages according to the International Union Against Cancer (UICC) 8th edition lung cancer TNM staging standard. Detect the subjects’ peripheral serum tumor markers, serum carcinoembryonic antigen (CEA), cytokeratin fragment 21-1 (CYFRA21-1), squamous cell carcinoma-associated antigen (SCCA), carbohydrate antigen 125 (CA125) and sugar Class antigen 199 (CA199). Compare the differences of serum CEA, CYFRA21-1, SCCA, CA125, CA199 levels in different clinical stages of elderly NSCLC patients, and the diagnostic value of the above indicators for elderly NSCLC patients was analyzed by receiver operating characteristic curve (ROC curve) and area under the curve (AUC). Results The smoking history, differentiation degree, lymph node metastasis and tumor diameter of elderly NSCLC patients with different clinical stages are significantly different; with the increase of NSCLC disease progression, the levels of serum CEA, CYFRA21-1, SCCA, CA125, and CA199 continue to increase, and serum tumors There is a significant correlation between the markers; serum CEA, CYFRA21-1, SCCA, CA125, CA199 have diagnostic value for the clinical staging of elderly NSCLC patients. Conclusions The elevation of serum CEA, CYFRA21-1, SCCA, CA125 and CA199 in elderly NSCLC patients is positively correlated with the degree of tumor malignancy. The detection of the above indicators is of great value for the early diagnosis and disease monitoring of elderly NSCLC.

show abstract

Overall survival for oncology drugs approved for genomic indications

Cited by 7 publications

References 9 publications

Tissue management in precision medicine: What the pathologist needs to know in the molecular era

Tissue management in precision medicine: What the pathologist needs to know in the molecular era

Timely, Cheap, or Risk-Free? The Effect of Regulation on the Price and Availability of New Drugs

Difference of serum tumor markers in different clinical stages of elderly patients with non-small cell lung cancer and evaluation of diagnostic value

Contact Info

Product

Resources

About